Altimmune, Inc. closed a $75 million direct offering to fund Phase 3 pemvidutide trials for MASH. Learn more about ALT stock ...
Brendan Saloner ([email protected]), Brown University, Providence, Rhode Island. Pooja Lagisetty, University of Michigan, Ann Arbor, Michigan. Access and scale are two sides of the same coin. Whereas ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果